The purpose of these clinical guidelines is to provide detailed policies and protocols of the Office Based Addiction Treatment program for the use of buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations) in the treatment of substance use disorders at BMC.
Section: Sample Protocols and Policies
Topic:
Clinical Workflow Support
Substance/Stimulant/Opiod Use Disorder
Toxicology
Substance/Stimulant/Opiod Use Disorder
Toxicology
Setting:
Drug Court
Outpatient
Outpatient
Type: Best Practice/Policy/Guideline/Procedure